Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03004 vs Risperdal Consta in Schizophrenia/Schizoaffective Disorder
NCT02091388Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Sep 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tofacitinib in schizophrenia and schizoaffective disorder (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Maximum Plasma Concentration at 113 days and Time to Maximum Plasma Concentration at 113 days. Started Sep 2014; status: completed.
02
Drugs
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02091388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091388.